11-beta-hydroxysteroid dehydrogenase 1 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-1411-beta-hydroxysteroid dehydrogenase 1 shows clinical signal disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P28845. Start with type 2 diabetes mellitus, then reuse UniProt P28845 as the stable protein anchor across project notes and exports.
Start with type 2 diabetes mellitus, then reuse UniProt P28845 as the stable protein anchor across project notes and exports.
11-beta-hydroxysteroid dehydrogenase 1 shows clinical signal disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.
Start review with type 2 diabetes mellitus because it currently carries clinical signal support. Linked drugs include AZD-4017, BI-187004, BMS-823778. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxy11-beta-hydroxysteroid dehydrogenase 1
Review this target as 11-beta-hydroxysteroid dehydrogenase 1, mapped to UniProt P28845. Sequence length is 292 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 11-beta-hydroxysteroid dehydrogenase 1 as ChEMBL target CHEMBL4235, mapped to UniProt P28845. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether 11-beta-hydroxysteroid dehydrogenase 1 is the right protein anchor across sources, using UniProt P28845 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why type 2 diabetes mellitus is currently framed as clinical signal support. It currently carries 3 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | 11-beta-hydroxysteroid dehydrogenase 1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P28845 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | 11-beta-hydroxysteroid dehydrogenase 1 |
| UniProt Accession | P28845 |
| Component Type | Protein |
| Sequence Length | 292 aa |
11-beta-hydroxysteroid dehydrogenase 1
Review this target as 11-beta-hydroxysteroid dehydrogenase 1, mapped to UniProt P28845. Sequence length is 292 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
11-beta-hydroxysteroid dehydrogenase 1 shows clinical signal disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.
Start review with type 2 diabetes mellitus because it currently carries clinical signal support. Linked drugs include AZD-4017, BI-187004, BMS-823778. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3897844 | 10.7 | IC50 | 0.02 | Preclinical |
| CHEMBL5289716 | 10.7 | IC50 | 0.02 | Preclinical |
| CHEMBL1096451 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL1096870 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL1098130 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL1098131 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL1098145 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL2377209 | 10.52 | EC50 | 0.03 | Preclinical |
| CHEMBL2152223 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL3609877 | 10.0 | IC50 | 0.1 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 157 | 1,546 | 7.3 |
| single protein format | 84 | 1,211 | 7.5 |
| assay format | 47 | 1,207 | 7.2 |
| microsome format | 15 | 105 | 6.8 |
| tissue-based format | 4 | 174 | 6.2 |
| cell-free format | 1 | 4 | 7.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 3 | 0 | — |